scispace - formally typeset
J

Jose F. Garcia-Bustos

Researcher at University of Melbourne

Publications -  63
Citations -  4829

Jose F. Garcia-Bustos is an academic researcher from University of Melbourne. The author has contributed to research in topics: Haemonchus contortus & Peptidoglycan. The author has an hindex of 28, co-authored 63 publications receiving 4370 citations. Previous affiliations of Jose F. Garcia-Bustos include University of Basel & Hospital General Universitario Gregorio Marañón.

Papers
More filters
Journal ArticleDOI

Thousands of chemical starting points for antimalarial lead identification

TL;DR: Chemical structures and associated data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host–pathogen interaction related targets.
Journal ArticleDOI

Nuclear protein localization.

TL;DR: Dans une derniere partie, le mecanisme de the translocation et sa regulation sont discutes.
Journal ArticleDOI

Two-dimensional single-cell patterning with one cell per well driven by surface acoustic waves

TL;DR: A new method for the patterning of multiple spatially separated single particles and cells using high-frequency acoustic fields with one cell per acoustic well is introduced, made possible by a hitherto unexplored regime where the acoustic wavelength is on the same order as the cell dimensions.
Journal ArticleDOI

Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.

TL;DR: With the aim of fuelling open‐source, translational, early‐stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible.
Journal ArticleDOI

Nitric oxide-producing CD11b+Ly-6G(Gr-1)+CD31(ER-MP12)+cells in the spleen of cyclophosphamide–treated mice: implications for T-cell responses in immunosuppressed mice

TL;DR: The results indicated that CTX might also cause immunosuppression by a mechanism involving the presence of immature myeloid cells with suppressor activity, which may have implications in clinical praxis since inappropriate immunotherapies in patients treated with intensive chemotherapy could lead to deleterious T-cell responses.